Investigational PAH Medication CXA-10

Trial Objective

Investigational PAH Medication CXA-10This study is to see whether a new study drug, called CXA-10, can help lower the pressure in the blood vessels from the heart to the lungs and improve heart health.

CXA-10 is a natural substance that is normally found in the body in low levels and is believed to reduce inflammation in the body. For this study, participants receive a right heart catheterization and a cardiac MRI during the screening visit and again approximately six months later.  They will perform a 6-Minute Walk Test at each study visit.  Visits are conducted once a month for five months, after which participants have the opportunity to enroll in a long-term extension study where everyone will receive CXA-10.


New enrollment for this trial is temporarily paused

Who Can Participate

Adults who have been diagnosed with PAH may be eligible to participate in this study.

Age: 18-80    Gender: Any Gender

Estimated Time Commitment

Up to 134 days

The screening period to see if participants are eligible to participate in the study lasts up to 30 days. Participants take the study drug for about 90 days. Lastly, the follow-up period lasts approximately 14 days. Participants will be asked to visit the clinic up to 8 times and have 4 phone calls with a member of the study team.

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Jennifer Underwood, Trial Coordinator

Jennifer Underwood

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Complexa, Inc.

Principal Investigators


Request More Information

Complete this form to learn more about this study and see if you qualify.